In a nutshell This study evaluated the safety and effectiveness of bortezomib (Velcade) and lenalidomide (Revlimid) for patients with multiple myeloma after stem cell transplantation. This study found this combination is effective for these patients, with few side effects. Some background Multiple myeloma (MM) is a type of cancer...
Read More
In a nutshell This article investigated the safety and effectiveness of pomalidomide (Pomalyst) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM) in a real-life setting. The authors concluded that this treatment is safe and effective in these patients. Some background Multiple myeloma...
Read More
In a nutshell This article investigated the safety and effectiveness of ixazomib (Ninlaro), melphalan (Alkeran), and prednisone (Deltasone) followed by maintenance (treatment meant to keep cancer from coming back) ixazomib for patients with multiple myeloma. The authors concluded that this...
Read More
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and...
Read More
In a nutshell This article investigated the safety and effectiveness of high-dose therapy with autologous stem cell transplantation (HDT-ASCT) and maintenance treatment (treatment meant to keep cancer from coming back) with lenalidomide (Revlimid) for patients with multiple myeloma. The authors concluded that this therapy is safe...
Read More
In a nutshell This study investigated the effects of adding elotuzumab to lenalidomide and dexamethasone to treat un-responsive multiple myeloma. The main finding was that patients treated with elotuzumab responded better to lenalidomide and dexamethasone. Some background Many patients respond well to treatment for multiple myeloma (MM). However some...
Read More
In a nutshell This paper reviewed the effect of thearpies that act on the immune system on the risk of infection. The study concluded that patients receiving these drugs are at a high risk of serious infection. Some background Treatment for multiple myeloma now generally includes immunomodulators and stem cell transplantation....
Read More
In a nutshell This paper reviewed the effect of elozutumab (Empliciti) in the treatment of relapsed or refractory multiple myeloma. This study concluded that elozutumab with lenalidomide (Revlimid) and dexamethasone (Ozurdex) can be considered in relapsed or refractory multiple myeloma. Some background Multiple myeloma...
Read More
In a nutshell This paper studied the risk of adverse events in patients who receive treatment for multiple myeloma. The use of new drugs increased the risk of low blood count, peripheral neuropathy and blood clots. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Multiple myeloma can be treated with drugs...
Read More
In a nutshell This study aims to test the safety and effectiveness of daratumumab in combination with carfilzomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. The main outcome to be measured will be the presence of disease. This study is being conducted in New Jersey, and New York. The details Multiple...
Read More
In a nutshell This study aims to compare ixazomib plus dexamethasone versus pomalidomide plus dexamethasone on survival in participants with relapse and/or refractory multiple myeloma. The outcome to be measured is the duration of time until disease progresses (worsens). The details Multiple myeloma is a cancer of the plasma cells in the...
Read More
In a nutshell This study aims to compare bortezomib, lenalidomide, and dexamethasone with carfilzomib, lenalidomide, and dexamethasone. The outcome to be measured is the overall survival (time from treatment until death from any cause). The details Multiple myeloma is a cancer of the plasma cells in the blood. Treatment for multiple myeloma...
Read More
